Stocks closed the week strong, with the S&P 500 just below a high. Google and DocuSign are among top stocks near buy points with accelerating growth. Apple WWDC and meme stocks are in focus. Read More...
Bloomberg
Fate of Biogen’s Stock Rides on Alzheimer’s Drug Decision
(Bloomberg) — For Biogen Inc., the Food and Drug Administration’s expected decision Monday on its Alzheimer’s drug is what a JPMorgan Chase & Co. analyst called “the mother of all binary events” — one that could send its shares veering sharply in either direction.If regulators give the company approval to market the drug, called aducanumab, the stock could surge to as much to $450, according to Wall Street analysts. Or it could tumble to $200 if the treatment is shot down, according to Cory Ka
Add Comment